In this #DoctorPodcasts Episode 149, we sit down with physician, Professor Carel le Roux, a global authority in metabolic medicine, #obesity and #diabetes to discuss the revolutionary shift in anti-obesity medications. We break down the differences between current leading GLP-1 drugs like #Ozempic (semaglutide) and #Mounjaro (tirzepatide), and look ahead to next-generation treatments. Dr. le Roux shares exclusive insights into the Phase 3 data for #Survodutide (Boehringer Ingelheim’s dual GLP-1/glucagon agonist), including its groundbreaking impact on visceral fat and #FattyLiverDisease (MASLD/MASH) via the SYNCHRONIZE trials. We also explore Eli Lilly’s upcoming triple agonist, Retatrutide. If you want to understand the future of weight loss, #MetabolicHealth, and how these drugs target the brain-gut axis, this deep dive is for you.0:00 - Introduction &amp; Guest Overview0:34 - Episode Welcome: Dr. Robert Cykiert0:48 - Entering Dublin: The GLP-1 Breakthrough2:27 - Long-Term Health Hazards of Obesity &amp; Diabetes3:24 - Why Obesity is a Disease of the Brain, Not Willpower4:57 - Ozempic (Semaglutide) vs. Mounjaro (Tirzepatide)6:16 - The Fatty Liver Disease (MASLD/MASH) Epidemic7:50 - The Truth About Visceral vs. Ectopic Fat10:04 - Survodutide Explained: The New Dual Agonist12:45 - Managing Side Effects &amp; Titration Schedules15:37 - Boehringer Ingelheim &amp; the Future of Obesity Medicine16:48 - Retatrutide: Eli Lilly’s New Triple Agonist18:26 - A 30-Second Guide for Doctors &amp; Patients20:11 - Closing Thoughts &amp; Patient Transformations

The Future of Weight Loss Drugs: Survodutide & Retatrutide. Ozempic & Mounjaro are only the beginning.

DoctorPodcasts || Cykiert Files

# Full Transcript

**Podcast:** DoctorPodcasts || Cykiert Files

## Transcript

But when you go and look at the Civudutide data, at any of the other data, the thing that stands out to me is the patients come back and they say, Doctor, this is amazing because I can do things. I can play with my children or my grandchildren. I can pick things up from the floor. You know, I am just so much more mobile than I've ever been. And I think this functional benefits that our patients get, you know, is really satisfying to me as a provider and it really drives the quality of health of my patients.

Hi, thanks for watching episode number 149 of the Doctor Podcast Show and I'm your host, Doctor Robert Cykiert. Please subscribe and follow Doctor Podcasts and like and repost this and your other favorite episodes. Really appreciate it. Today's show is about the very hot topic of the GLP-1 drugs like Ozempic, Wigovi, Mounjaro, Zetbound. We've crossed the Atlantic Ocean today and are in Dublin, Ireland today with one of the world's leading experts on GLP-1 drugs,

obesity, diabetes and metabolic syndrome. Dr. Krell Leroux is a physician and international leading authority in metabolic medicine and obesity research. He's the chair of chemical pathology at University College Dublin and serves as a consultant chemical pathologist at St. Vincent's University Hospital and the National Maternity Hospital in Dublin. He's the director of the Metabolic Medicine Group at University College Dublin as well.

He's originally from South Africa and completed specialist training in metabolic medicine at St. Bartholomew's and Hammersmith Hospital in London and earned his PhD degree on top of that at Imperial College London. Professor Leroux is internationally recognized for his groundbreaking work on gut brain communication, the mechanisms of bariatric surgery and how gut hormones regulate appetite, weight and metabolic health.

His research has significantly advanced our understanding of obesity as a chronic disease and has influenced the development and clinical application of modern anti-obesity medications, including GLP-1 drugs based therapies. He is highly respected clinician, scientist and continues to provide multidisciplinary care to patients with obesity and its complications while leading translational research and clinical trials that bridge the bench and the bedside.

So, Professor Leroux, thank you very much for joining us today. We really appreciate your time and expertise. To start, can we walk through how the major health hazards of obesity, type 2 diabetes and metabolic syndrome affect our lives, especially long term risks that many people still underestimate? Yeah, thank you very much for having me. And we now understand that the disease of obesity really drives more than 220 complications.

And the problem with these complications is not only do they make people live shorter, they also reduce the quality of life of people at the same time. So what we now want to...

The Future of Weight Loss Drugs: Survodutide & Retatrutide. Ozempic & Mounjaro are only the beginning.

Transcript

Built for investment professionals

Every day you wait, your competitors are finding
edge in conversations you're not hearing.

The Future of Weight Loss Drugs: Survodutide & Retatrutide. Ozempic & Mounjaro are only the beginning.

Transcript

Built for investment professionals

Every day you wait, your competitors are findingedge in conversations you're not hearing.

Every day you wait, your competitors are finding
edge in conversations you're not hearing.